LivaNova PLC reported solid first-quarter 2025 results, with total net revenue increasing 7.4% to $316.9 million, or 10.4% organically, compared to $294.9 million in the first quarter of 2024. Adjusted diluted earnings per share were $0.88, up from $0.73 in the prior-year quarter. The Cardiopulmonary segment grew 13.1% to $176.3 million, driven by Essenz Perfusion System sales and consumables demand.
Neuromodulation revenue increased 3.8% to $138.9 million, with strength in Europe and Rest of World regions. U.S. Epilepsy growth was 2.2%, partially impacted by procedure deferrals related to a field safety notification. The company recorded a GAAP diluted loss per share of $6.01, primarily due to a €333.3 million ($360.4 million) liability for the SNIA environmental litigation.
LivaNova updated its full-year 2025 guidance, now expecting revenue growth between 6.0% and 7.0% on a constant-currency basis, or 7.0% to 8.0% organically. Adjusted diluted earnings per share are projected in the range of $3.60 to $3.70, which incorporates the SNIA impact and tariffs, reflecting stronger operational performance expectations despite these factors. The company also repaid $200.0 million of its Term Facilities on May 2, 2025, following the SNIA resolution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.